Latest Small hairpin RNA Stories
DALLAS, October 28, 2014 /PRNewswire/ -- RnRMarketResearch.com adds RNA Interference Screening Trends 2014 market research and industry survey report to the Biotechnology
The human immune system has a natural ability to identify and attack tumor cells.
In a paper published in the October 2011 issue of Experimental Biology and Medicine, a team of researchers at Columbia University Medical Center led by Stephen Tsang, MD, Ph.D have achieved temporary functional preservation of photoreceptors in a mouse model for retinitis pigmentosa (RP) using novel bipartite gene therapy.
LONDON, April 27, 2011 /PRNewswire-FirstCall/ -- Silence Therapeutics Plc (AIM: SLN), a leading international RNAi therapeutics company, today announces its results for the year ended 31 December 2010. Analyst Conference Call: There will be a call for analysts today at 14:30 BST / 09:30 ET.
In its continuing support of the DECIPHER Projectâ€”an open access platform for genome-wide RNAi screening and analysis, Cellecta released the 3rd DECIPHER shRNA Expression Library Module which targets an additional 5,000 human genes enabling researchers to now analyze the functionality of over 15,000 human genes for various biological processes with all three human modules. Mountain View, CA (PRWEB) February 25, 2011 Today, Cellecta, Inc.
LAS VEGAS, Oct. 21 /PRNewswire/ -- Altogen Biosystems announced the release of its second generation of in vivo RNAi transfection reagent (http://www.altogen.com/mirna.php) in the company's popular in vivo delivery product line: PEG-Liposome siRNA In Vivo Transfection Kit.
LONDON, Aug. 11 /PRNewswire/ -- Silence Therapeutics plc (AIM: SLN) ("Silence" or the "Company") announces the issuance of United States patent 7,772,203, titled "Methods and Compositions for Controlling Efficacy of RNA Silencing," by the United States Patent and Trademark Office (USPTO).
LONDON, June 9 /PRNewswire/ -- Silence Therapeutics plc (AIM: SLN) ("Silence" or the "Company") announces the issuance of United States patent 7,732,593, titled Methods and Compositions For Controlling Efficacy of RNA Silencing, by the United States Patent and Trademark Office (USPTO).